相关实验视频

Updated: Jan 15, 2026

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

口服益生菌使用对HR-HPV清除的影响,一项回顾性研究

Mustafa Şahin¹, Özgün Ceylan¹

¹Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey.

International journal of women's health

|October 10, 2025

概括

在这项研究中,口服Lactobacillus rhamnosus并没有改善高危人乳头瘤病毒 (HR-HPV) 清除或宫细胞学结果. 需要进一步的研究来证实这些关于HR-HPV感染的发现.

科学领域:

妇科妇科医生妇科
微生物学微生物学
在瘤学瘤学.

背景情况:

高风险的人类乳头瘤病毒 (HR-HPV) 感染是导致子宫癌的主要原因.
宫细胞学和HPV DNA测试对于查和诊断至关重要.
益生菌,如Lactobacillus rhamnosus,正在探索潜在的治疗益处.

研究的目的:

为了研究口服Lactobacillus rhamnosus在清除HR-HPV感染中的疗效.
评估口服L. rhamnosus对HR-HPV阳性患者宫细胞学结果的影响.

主要方法:

一项回顾性观察性研究分析了218名HR-HPVDNA阳性患者没有高度病变的数据.
一个研究小组 (n=105) 接受了口服的L. rhamnosus和 (V-Flora) 三个月.
在6个月和12个月的研究和对照组之间,HR-HPV DNA和宫细胞学结果进行了比较.

主要成果:

在6个月和12个月的L. rhamnosus用户和非用户之间没有观察到HR-HPV清除的显著差异.
宫细胞学结果也显示,两组之间没有显著差异.
统计分析 (危险比和p值) 显示L. rhamnosus对HR-HPV清除或细胞学没有影响.

结论:

口服Lactobacillus rhamnosus并没有对HR-HPV清除或宫细胞学结果产生有益影响.
研究结果表明,L. rhamnosus可能无法有效管理HR-HPV感染.
需要进一步的研究来验证这些结果并探索替代干预措施.

关键词:

HR-HPV 清除时间乳杆菌 rhamnosusus 的乳杆菌.人类乳头瘤病毒人类乳头瘤病毒口服益生菌的使用.阴道的微生物群.

更多相关视频

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...